期刊文献+

Treatment of early stage(T1) esophageal adenocarcinoma:Personalizing the best therapy choice

Treatment of early stage(T1) esophageal adenocarcinoma:Personalizing the best therapy choice
下载PDF
导出
摘要 Esophagectomy is considered the primary form of management for esophageal adenocarcinoma(EAC);however,the surgery is associated with high rates of morbidity and mortality.For patients with early-stage EAC,endoscopic resection(ER)presents a potential curative treatment option that is less invasive and carries fewer risks procedure related risks,but it is associated with higher rates of cancer recurrence following the procedure.For some patients,age and comorbidities may prevent them from having esophagectomy as a treatment option,while other patients may be operative candidates but do not wish to undergo esophagectomy for a variety of reasons related to their values and preferences.Furthermore,while anxiety of cancer recurrence following ER may significantly diminish a patient’s quality of life(QOL),so might the morbidity surrounding esophagectomy.In addition to considering health status,patient preferences,and impacts on QOL,physicians and patients must also consider what treatments would be both beneficial and available to the patient,considering esophagectomy methods-minimally invasive vs open-or the use of chemoradiotherapy in addition to ER.Our article reviews and summarizes available treatment options for patients with early EAC and their potential effects on the health and wellbeing of patients based on the current data.We conclude with a request for more research of available options for early EAC patients,the conditions that determine when each option should be employed,and their effects not only on patient health but also QOL. Esophagectomy is considered the primary form of management for esophageal adenocarcinoma(EAC);however,the surgery is associated with high rates of morbidity and mortality.For patients with early-stage EAC,endoscopic resection(ER) presents a potential curative treatment option that is less invasive and carries fewer risks procedure related risks,but it is associated with higher rates of cancer recurrence following the procedure.For some patients,age and comorbidities may prevent them from having esophagectomy as a treatment option,while other patients may be operative candidates but do not wish to undergo esophagectomy for a variety of reasons related to their values and preferences.Furthermore,while anxiety of cancer recurrence following ER may significantly diminish a patient’s quality of life(QOL),so might the morbidity surrounding esophagectomy.In addition to considering health status,patient preferences,and impacts on QOL,physicians and patients must also consider what treatments would be both beneficial and available to the patient,considering esophagectomy methods-minimally invasive vs open-or the use of chemoradiotherapy in addition to ER.Our article reviews and summarizes available treatment options for patients with early EAC and their potential effects on the health and wellbeing of patients based on the current data.We conclude with a request for more research of available options for early EAC patients,the conditions that determine when each option should be employed,and their effects not only on patient health but also QOL.
出处 《World Journal of Meta-Analysis》 2019年第9期406-417,共12页 世界荟萃分析杂志
关键词 ESOPHAGEAL cancer ADENOCARCINOMA T1b ESOPHAGECTOMY Endoscopic RESECTION CHEMORADIOTHERAPY Quality of life Esophageal cancer Adenocarcinoma T1b Esophagectomy Endoscopic resection Chemoradiotherapy Quality of life
  • 相关文献

参考文献2

二级参考文献14

  • 1Lv, Jin,Cao, Xiu-Feng,Zhu, Bin,Ji, Lv,Tao, Lei,Wang, Dong-Dong.Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma[J].World Journal of Gastroenterology,2010,16(13):1649-1654. 被引量:49
  • 2Yoichi Hamai,Jun Hihara,Junya Taomoto,Ichiko Yamakita,Yuta Ibuki,Morihito Okada.Hemoglobin Level Influences Tumor Response and Survival After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma[J].World Journal of Surgery.2014(8)
  • 3R. L. G. M. Blom,M. N. Sosef,M. Nap,G. Lammering,F. Berkmortel,M. C. C. M. Hulshof,S. L. Meijer,H. W. Wilmink,M. I. Berge Henegouwen.Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma[J].Dis Esophagus.2014(4)
  • 4K. Kumagai,I. Rouvelas,J. A. Tsai,D. Mariosa,F. Klevebro,M. Lindblad,W. Ye,L. Lundell,M. Nilsson.Meta‐analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro‐oesophageal junctional cancers[J].Br J Surg.2014(4)
  • 5Chien-Hong Chiu,Yin-Kai Chao,Hsien-Kun Chang,Chen-Kan Tseng,Sheng-Chieh Chan,Yun-Hen Liu,Wei-Hsun Chen.Interval Between Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma: Does Delayed Surgery Impact Outcome?[J].Annals of Surgical Oncology.2013(13)
  • 6M. Odenthal,E. Bollschweiler,P.P. Grimminger,W. Schr?der,J. Brabender,U. Drebber,A.H. H?lscher,R. Metzger,D. Vallb?hmer.MicroRNA profiling in locally advanced esophageal cancer indicates a high potential of miR‐192 in prediction of multimodality therapy response[J].Int J Cancer.2013(10)
  • 7Guillaume Piessen,Mathieu Messager,Xavier Mirabel,Nicolas Briez,William B. Robb,Antoine Adenis,Christophe Mariette.Is There a Role for Surgery for Patients with a Complete Clinical Response after Chemoradiation for Esophageal Cancer? An Intention-to-Treat Case-Control Study[J].Annals of Surgery.2013(5)
  • 8Ravi Shridhar,Sarah E. Hoffe,Khaldoun Almhanna,Jill M. Weber,Michael D. Chuong,Richard C. Karl,Kenneth Meredith.Lymph Node Harvest in Esophageal Cancer After Neoadjuvant Chemoradiotherapy[J].Annals of Surgical Oncology.2013(9)
  • 9R. L. G. M. Blom,M. Heijl,J. H. G. Klinkenbijl,J. J. G. H. M. Bergman,J. W. Wilmink,D. J. Richel,M. C. C. M. Hulshof,J. B. Reitsma,O. R. C. Busch,M. I. Berge Henegouwen.Neoadjuvant chemoradiotherapy followed by esophagectomy does not increase morbidity in patients over 70[J].Dis Esophagus.2013(5)
  • 10Shau-Hsuan Li,Eng-Yen Huang,Hung-I Lu,Wan-Ting Huang,Chueh-Chuan Yen,Wen-Chien Huang,Chang-Han Chen.Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma[J].The Journal of Thoracic and Cardiovascular Surgery.2012(6)

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部